ASCO 2019: Maintenance Therapy with PARP Inhibitor Olaparib Delays Progression of BRCA-related Pancreatic Cancer

Hedy L. Kindler | ASCO 2019 | 3. Juni 2019

Speaker: Hedy L. Kindler

This is the first phase III trial to evaluate efficacy of maintenance treatment with a PARP inhibitor, olaparib, for Pancreatic cancer patients with a germline BRCA1and/or BRCA2mutation. In this MEDtalk, Hedy L. Kindler, concludes, that Maintenance olaparib provided a statistically significant and clinically meaningful improvement in PFS for this group of patients.